Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Johanna W. Wilmink

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1677-1278; OpenAlex author ID A5110360711. Sources: OpenAlex.

Their work

Papers
147 (first author 1, last author 16)
Trials
0
Grants
0
Labs led
2
Collaborators
350
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 4 papers · 2016: 3 papers · 2017: 3 papers · 2018: 9 papers · 2019: 8 papers · 2020: 14 papers · 2021: 16 papers · 2022: 12 papers · 2023: 16 papers · 2024: 17 papers · 2025: 19 papers · 2026: 24 papers

Papers 50 of 147

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Prevention of Venous Thromboembolism in Patients With Pancreatic Cancer: A Nationwide Survey. Co-author DOI 10.1002/cam4.72306↗
  3. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  4. The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. Co-author DOI 10.1007/s00520-026-10568-3↗
  5. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Co-author DOI 10.1016/j.ejca.2026.116263↗
  6. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. Last author DOI 10.1016/j.ejca.2026.116683↗
  7. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  8. Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Last author DOI 10.1016/j.ejca.2026.116943↗
  9. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116956↗
  10. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  11. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  12. Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2026.100311↗
  13. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  14. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Co-author DOI 10.1016/s1470-2045(25)00729-6↗
  15. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  16. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  17. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  18. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  19. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Co-author DOI 10.1097/j.pain.0000000000004059↗
  20. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  21. Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. Co-author DOI 10.1158/0008-5472.can-24-4707↗
  22. Pancreatic Ductal Adenocarcinoma with Atypical Genomic Profile: A Case of Long-Term Survival with KRAS-Wildtype, Microsatellite Instability and High Tumor Muta… Co-author DOI 10.1159/000552404↗
  23. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  24. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  25. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  26. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  27. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  28. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  29. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  30. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  31. KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer. Co-author DOI 10.1016/j.medj.2025.100601↗
  32. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Last author DOI 10.1016/j.pan.2025.03.011↗
  33. Reply to Comments on "Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort". Last author DOI 10.1016/j.pan.2025.07.012↗
  34. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(25)00261-2↗
  35. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  36. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  37. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  38. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  39. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  40. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  41. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  42. 18F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study. Co-author DOI 10.1186/s40644-025-00822-y↗
  43. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  44. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  45. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  46. MR Elastography of the Pancreas: Bowel Preparation and Repeatability Assessment in Pancreatic Cancer Patients and Healthy Controls. Co-author DOI 10.1002/jmri.28918↗
  47. Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study. Co-author DOI 10.1016/j.ejca.2024.114117↗
  48. Impact of Short-Course Palliative Radiation Therapy on Pancreatic Cancer-Related Pain: Prospective Phase 2 Nonrandomized PAINPANC Trial. Co-author DOI 10.1016/j.ijrobp.2023.08.055↗
  49. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  50. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗

Closest collaborators

The 25 strongest of 350 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 106 shared papers, 2015–2026 · strength 14.56
  2. Hanneke W.M. van Laarhoven · 63 shared papers, 2015–2026 · strength 8.38
  3. Bas Groot Koerkamp · 59 shared papers, 2018–2026 · strength 8.34
  4. Judith de Vos‐Geelen · 49 shared papers, 2018–2026 · strength 8.15
  5. Marjolein Y.V. Homs · 45 shared papers, 2019–2026 · strength 7.44
  6. Casper H.J. van Eijck · 50 shared papers, 2018–2026 · strength 7.36
  7. Hjalmar C. van Santvoort · 45 shared papers, 2016–2026 · strength 6.52
  8. Ignace H. J. T. de Hingh · 41 shared papers, 2016–2026 · strength 6.03
  9. Izaak Quintus Molenaar · 41 shared papers, 2016–2026 · strength 5.80
  10. Lydia G. van der Geest · 29 shared papers, 2017–2026 · strength 4.83
  11. Geertjan van Tienhoven · 36 shared papers, 2015–2026 · strength 4.59
  12. Bert A. Bonsing · 29 shared papers, 2018–2026 · strength 3.94
  13. Vincent Erwin de Meijer · 24 shared papers, 2020–2026 · strength 3.79
  14. Martijn W.J. Stommel · 24 shared papers, 2019–2026 · strength 3.76
  15. Geert Kazemier M · 19 shared papers, 2015–2026 · strength 2.98
  16. Lois A. Daamen · 16 shared papers, 2019–2026 · strength 2.81
  17. Thomas F. Stoop · 12 shared papers, 2021–2026 · strength 2.13
  18. Merlijn U.J.E. Graus · 10 shared papers, 2023–2026 · strength 2.10
  19. Nadia Haj Mohammad · 20 shared papers, 2016–2025 · strength 2.10
  20. Jeanin Elise van Hooft · 14 shared papers, 2017–2026 · strength 2.04
  21. Quisette P. Janssen · 14 shared papers, 2019–2026 · strength 1.96
  22. Maarten F. Bijlsma · 13 shared papers, 2015–2026 · strength 1.92
  23. Jacob L. van Dam · 11 shared papers, 2021–2026 · strength 1.73
  24. Sebastiaan Festen · 12 shared papers, 2020–2026 · strength 1.66
  25. Gijs A. Patijn · 13 shared papers, 2020–2026 · strength 1.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.